Skip to content

Hematology and Transfusion Medicine

Share This Page

The Hematology and Transfusion Medicine Research Program was founded in 2023 by Dr. Mohammed Refaei. The program participates in multicenter clinical trials in the areas of venous thromboembolism and stem cell transplants. Additionally, the program participates in multicenter quality improvement projects.

Current Team Members

Dr. Mohammad Refaei
Physician Lead

Ramsha Faisal
Clinical Research Coordinator

Ongoing Studies

A Clinical Prediction Model for the Diagnosis of Immune Thrombocytopenia (ITP):

This is a national retrospective study to perform an external validation of the Predict-ITP score for diagnosis of ITP in academic and community hematology settings across Canada.

EPCATIII

EPCATIII: Extended Venous Thromboembolism Prophylaxis Comparing Rivaroxaban and Aspirin to Aspirin Alone Following Total Hip and Knee Arthroplasty

Venous thromboembolism (formation of blood clots in veins) may occur in patients undergoing total hip or total knee replacement. This study compares aspirin alone to rivaroxaban and aspirin in the prevention of venous thromboembolism.

Patients and Caregiver Priorities for Quality Improvement on General Medical Wards:

The heterogeneity and complexity of general internal medicine has complicated quality improvement (QI) efforts. These QI priorities reflect gaps from knowledge to action. This is a national project engaging diverse groups of patients and their caregivers in a quality improvement priority-setting. This QI project directly informs initiatives on general medical wards with direct relevance to the health of Canadians.

PATH III

PATH III: Platelet Transfusions in Hematopoietic Stem Cell Transplantation

Patients undergoing autologous hematopoietic stem cell transplants (ASCT) typically receive platelet transfusions to prevent bleeding. However, this routine practice may be unnecessary and could pose risks to patients. An alternative strategy to prevent bleeding and reduce the need for platelet transfusions is Tranexamic Acid. This study evaluates the safety and effectiveness of preventive Tranexamic Acid, (with therapeutic platelet transfusions provided in the event of active bleeding), compared to preventive platelet transfusions in ASCT patients.

Read Niagara Health's affiliated publications

« Go Back

Niagara Health System